衛材在(zai)華企業(ye)隸屬(shu)于衛材株式(shi)會社,衛材株式(shi)會社是一家(jia)以(yi)研究開發醫藥產品為主的跨(kua)國公司,總部(bu)設在(zai)日本東(dong)京。
衛(wei)(wei)(wei)材(cai)中國自(zi)上世紀90年(nian)(nian)(nian)代初(chu)進入中國市場以來(lai)順(shun)利發(fa)展壯大。自(zi)1991年(nian)(nian)(nian)先后成(cheng)(cheng)立沈陽衛(wei)(wei)(wei)材(cai)制藥(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)和衛(wei)(wei)(wei)材(cai)(蘇州)制藥(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si),并(bing)于2002年(nian)(nian)(nian)正(zheng)式更名為(wei)衛(wei)(wei)(wei)材(cai)(中國)藥(yao)(yao)業(ye)(ye)(ye)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)。伴隨著中國業(ye)(ye)(ye)務(wu)的(de)(de)發(fa)展,于2010年(nian)(nian)(nian)成(cheng)(cheng)立衛(wei)(wei)(wei)材(cai)(蘇州)貿易有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si),于2014年(nian)(nian)(nian)成(cheng)(cheng)立衛(wei)(wei)(wei)材(cai)(中國)投(tou)資有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si),并(bing)于2015年(nian)(nian)(nian)通過全額收購本地仿制藥(yao)(yao)企業(ye)(ye)(ye)正(zheng)式成(cheng)(cheng)立衛(wei)(wei)(wei)材(cai)(遼(liao)寧(ning))制藥(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)。至此,形成(cheng)(cheng)了以衛(wei)(wei)(wei)材(cai)(中國)投(tou)資有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)為(wei)資控管理,以衛(wei)(wei)(wei)材(cai)(中國)藥(yao)(yao)業(ye)(ye)(ye)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、衛(wei)(wei)(wei)材(cai)(遼(liao)寧(ning))制藥(yao)(yao)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)、衛(wei)(wei)(wei)材(cai)(蘇州)貿易有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)為(wei)業(ye)(ye)(ye)務(wu)支撐的(de)(de)發(fa)展模式。為(wei)適應中國業(ye)(ye)(ye)務(wu)的(de)(de)迅速發(fa)展,2014年(nian)(nian)(nian)11月衛(wei)(wei)(wei)材(cai)(中國)藥(yao)(yao)業(ye)(ye)(ye)有(you)(you)(you)限(xian)(xian)公(gong)(gong)(gong)(gong)司(si)(si)(si)(si)注射劑工廠竣工, 2017年(nian)(nian)(nian)11月新(xin)固體制劑廠房落成(cheng)(cheng),衛(wei)(wei)(wei)材(cai)中國的(de)(de)產能得到迅速提(ti)升。
目前(qian),總注冊資本10,854萬美金。已形成以神經科學領域、腫瘤(特藥)領域、消(xiao)化(hua)肝(gan)病(bing)領域為主要領域,拓展(zhan)仿(fang)制藥領域,多達數十種藥品在中國(guo)銷售的發展(zhan)規模。
未來,蘇(su)州(zhou)工廠(chang)除(chu)滿足中國患(huan)者臨床(chuang)用藥的(de)需(xu)求外,將向亞洲(zhou)其它國家和地區同(tong)樣提供高品(pin)質滿足患(huan)者需(xu)求的(de)產品(pin)。